Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares stood at 0.73 million during the last session, with the company’s beta value hitting 2.22. At the close of trading, the stock’s price was $0.95, to imply an increase of 6.26% or $0.06 in intraday trading. The ADAP share’s 52-week high remains $2.05, putting it -115.79% down since that peak but still an impressive 55.79% since price per share fell to its 52-week low of $0.42. The company has a valuation of $243.17M, with an average of 1.19 million shares in intraday trading volume over the past 10 days and average of 1.77 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Adaptimmune Therapeutics Plc ADR (ADAP), translating to a mean rating of 1.80. Of 6 analyst(s) looking at the stock, 1 analyst(s) give ADAP a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.15.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
After registering a 6.26% upside in the last session, Adaptimmune Therapeutics Plc ADR (ADAP) has traded red over the past five days. The 5-day price performance for the stock is -2.68%, and -14.32% over 30 days. With these gigs, the year-to-date price performance is 19.92%. Short interest in Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw shorts transact 7.0 million shares and set a 5.78 days time to cover.
The extremes give us $1 and $4 for target low and target high price respectively. As such, ADAP has been trading -321.05% off suggested target high and -5.26% from its likely low.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Looking at statistics comparing Adaptimmune Therapeutics Plc ADR share performance against respective industry, we note that the company has outperformed competitors. Adaptimmune Therapeutics Plc ADR (ADAP) shares are -30.58% down over the last 6 months, with its year-to-date growth rate higher than industry average at 61.90% against 17.60%. Revenue is forecast to grow 25.00% this quarter before jumping 50.00% for the next one. The rating firms project that company’s revenue will grow 166.90% compared to the previous financial year.
Revenue forecast for the current quarter as set by 8 analysts is 11.1M. Meanwhile, for the current quarter, a total of 9 analyst(s) estimate revenue growth to 12.25M.Earnings reports from the last fiscal year show that sales brought in 7.32M and 231k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 51.70% before jumping 5,203.00% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 10.30% for the past 5-year period. While 2024 is set for a 46.18% return in earnings, projections for the next 5 years are at 1.00% annually.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR has its next earnings report out on 2024-Aug-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Adaptimmune Therapeutics Plc ADR insiders hold 0.38% of total outstanding shares, with institutional holders owning 61.81% of the shares at 62.04% float percentage. In total, 61.81% institutions holds shares in the company, led by MATRIX CAPITAL MANAGEMENT COMPANY, LP. As of 2024-06-30, the company held over 38.97 million shares (or 16.1135% of shares), all amounting to roughly $38.0 million.
The next major institution holding the largest number of shares is ECOR1 CAPITAL, LLC with 27.4 million shares, or about 11.3299% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $26.72 million.
We also have SPDR Portfolio Developed World ex-US ETF and Trust for Professional Managers-ActivePassive International Equity ETF as the top two Mutual Funds with the largest holdings of the Adaptimmune Therapeutics Plc ADR (ADAP) shares. Going by data provided on Aug 31, 2024 , SPDR Portfolio Developed World ex-US ETF holds roughly 246.31 shares. This is just over 0.10% of the total shares, with a market valuation of $0.23 million. Data from the same date shows that the other fund manager holds a little less at 165.66, or 0.06% of the shares, all valued at about 0.16 million.
